Drug intelligence / Profile preview

aspirin + clopidogrel + cilostazol + dipyridamole

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

This is a theoretical combination of four antiplatelet medications. While each drug is used in various dual antiplatelet therapy (DAPT) regimens, there is no established clinical use of all four medications simultaneously. Each component has distinct mechanisms of action: aspirin inhibits cyclooxygenase, clopidogrel is a P2Y12 receptor antagonist, cilostazol is a phosphodiesterase inhibitor, and dipyridamole inhibits adenosine deaminase and phosphodiesterase.

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ENT (Equilibrative nucleoside transporter family)P2Y12 (Purinergic P2Y12 receptor)PDE5 (Phosphodiesterase 5A)PDE3ADA (Adenosine deaminase)PDE (Phosphodiesterase family)

Beyond the preview

Go deeper on aspirin + clopidogrel + cilostazol + dipyridamole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspirin + clopidogrel + cilostazol + dipyridamole.